Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Punekar, Yogesh Suresh ^a   Landis, Sarah H ^a   Wurst, Keele ^b,c   Le, Hoa ^b,c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c PAREXEL INTERNATIONAL   (United States)

Author keywords

COPD; Costs; Long acting bronchodilators; Primary care; Resource use; Retrospective cohort study; UK

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SCORING SYSTEM; UNITED KINGDOM; AMBULATORY CARE; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFECTS; ECONOMICS; FACTUAL DATABASE; GENERAL PRACTICE; HEALTH CARE PLANNING; LUNG; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DISEASE PROGRESSION; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; GENERAL PRACTICE; GLUCOCORTICOIDS; HEALTH RESOURCES; HUMANS; LUNG; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; OFFICE VISITS; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84960392215     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0295-2     Document Type: Article

References (30)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2015. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdf. Accessed 30 April 2015.
2. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update) NICE guidelines. 2010. http://www.nice.org.uk/nicemedia/live/13029/49397/49397.pdf. Accessed 30 April 2015.
3. Rosenberg SR, Kalhan R. An integrated approach to the medical treatment of chronic obstructive pulmonary disease. Med Clin North Am. 2012;96:811-26.
4. Diette GB, Orr P, McCormack MC, Gandy W, Hamar B. Is pharmacologic care of chronic obstructive pulmonary disease consistent with the guidelines? Popul Health Manag. 2010;13:21-6.
5. Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin. 2011;27:1425-9.
6. Salinas GD, Williamson JC, Kalhan R, Thomashow B, Scheckermann JL, Walsh J, et al. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis. 2011;6:171-9.
7. Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, Leuppi JD. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss medical weekly. 2010; doi: 10.4414/smw.2010.13053.
8. Perez X, Wisnivesky JP, Lurslurchachai L, Kleinman LC, Kronish IM. Barriers to adherence to COPD guidelines among primary care providers. Respir Med. 2012;106:374-81.
9. Dransfield MT, Bailey W, Crater G, Emmett A, O'Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2011;20:46-53.
10. Punekar YS, Shukla A, Mullerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9:65-73.
11. Punekar YS, Wurst K, Shukla A. Resource Use and Costs up to Two Years Post Diagnosis Among Newly Diagnosed COPD Patients in the UK Primary Care Setting: A Retrospective Cohort Study. COPD. 2015;12(3):267-75.
12. Murtagh E, O'Neill C, McAllister D, Kee F, Macmahon J, Heaney LG. A Cross-Sectional Comparison of Direct Medical Care Costs among COPD and Asthma Patients Living in the Community in Northern Ireland. Treat Respir Med. 2006;5:495-501.
13. Blanchette CM, Gross NJ, Altman P. Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend. Am Health Drug Benefits. 2014;7:98-106.
14. Simon-Tuval T, Maimon N. Tiotropium as part of inhaled polytherapy: Adherence and associated health-care utilization. Respirology. 2015;20:304-11.
15. Penning-van Beest F, van Herk-Sukel M, Gale R, Lammers JW, Herings R. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir Med. 2011;105:259-65.
16. Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care. PLoS One. 2014;9, e105296.
17. Datalink. CPRD. http://www.cprd.com/home/. Accessed 30 April 2015.
18. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract. 2010;11:1.
19. Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509-16.
20. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-16.
21. Department of Health, UK. NHS reference costs 2013-14. Available at: https://www.gov.uk/government/collections/nhs-reference-costs. Accessed on April 30, 2015.
22. Buckingham RJ, Lowe D, Pursey NA, Roberts CM, Stone RA. Report of the National Chronic Obstructive Pulmonary Disease Audit 2008: clinical audit of COPD exacerbations admitted to acute NHS units across the UK: Royal College of Physicians, British Thoracic Society, British Lung Foundation. 2008. https://www.rcplondon.ac.uk/sites/default/files/report-of-the-national-copd-audit-2008-clinical-audit-of-copd-exacerbations-admitted-to-acute-nhs-units-across-the-uk.pdf. Accessed 30 April 2015.
23. Personal Social Services Research Unit U. Unit Costs of Health and Social Care 2014. Available at: http://www.pssru.ac.uk/project-pages/unit-costs/2014/. Accessed on September 14, 2015.
24. Prescribing and Primary Care team, Health and Social Care Information Centre. Prescription Cost Analysis, England 2014. http://www.hscic.gov.uk/searchcatalogue?productid=14494&q=title%3a%22Prescription+Cost+Analysis%2c+England%22+!quarterly&sort=Relevance&size=10&page=1#top. Accessed 30 April 2015.
25. Braido F, Baiardini I, Scichilone N, Sorino C, Di Marco F, Corsico A, et al. Disability in moderate chronic obstructive pulmonary disease: prevalence, burden and assessment - results from a real-life study. Respiration. 2015;89(2):100-6.
26. Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889-904.
27. Stuart BC, Simoni-Wastila L, Zuckerman IH, Davidoff A, Shaffer T, Yang HW, et al. Impact of maintenance therapy on hospitalization and expenditures for medicare beneficiaries with chronic obstructive pulmonary disease. Am J Geriatr Pharmacother. 2010;8(5):441-53.
28. Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, et al. Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435-41.
29. Simoni-Wastila L, Wei YJ, Qian J, Zuckerman IH, Stuart B, Shaffer T, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a medicare population. Am J Geriatr Pharmacother. 2012;10(3):201-10.
30. Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res. 2008;9:62.